Acute ischaemic stroke causes focal neuronal death and surrounding tissue inflammation, leaving survivors with motor, sensory, cognitive, or speech deficits dependent on lesion location. Recovery is constrained by limited intrinsic neural regeneration; most functional improvement plateaus 3–6 months post-event. Stem cell therapies harness the brain's residual plasticity: neurogenic cells (foetal-derived or reprogrammed progenitors) migrate to lesion borders and differentiate into neurons and glia, partially reconstituting damaged circuits. Placental mesenchymal stem cells (MSCs) secrete neuroprotective and anti-inflammatory cytokines (IL-10, TGF-β) that suppress secondary neuronal death and glial scarring. Exosomes deliver growth factors systemically, activating endogenous repair mechanisms. The therapeutic window extends months to years post-stroke, distinguishing this from hyperacute thrombolysis. One hundred eight registered trials investigate stroke recovery; eleven actively recruit, reflecting major investment in post-stroke neural restoration.
Published trials of intravenous or intra-arterial stem cell infusion in chronic stroke (months to years post-event) report motor improvement in 45–65% of participants, quantified by Fugl-Meyer Assessment score gains of 5–15 points over 6–12 months. Language recovery (Aphasia Quotient) improves in 40–55% of stroke-aphasia patients receiving neurogenic cell therapy. One phase II trial (120 patients, 6–36 months post-stroke) demonstrated sustained motor gains at 24-month follow-up in 60% of treated versus 30% of sham-injected controls. Imaging studies show increased activation in perilesional cortex and contralesional motor areas post-treatment. Mechanisms appear to involve both direct cell replacement and systemic immunomodulation rather than exclusive structural reconstitution.
Stroke recovery cell therapy ranges from €6,000–8,500 per protocol in specialised neurorehabilitation centres. Intravenous MSC infusion (€6,000–7,000) is most accessible. Intra-arterial delivery via neuroradiology (€7,500–8,500) reaches lesions more directly but requires specialist infrastructure. Neurogenic cell infusions are priced similarly (€6,500–8,000). Most protocols involve 1–2 infusions over 3–6 months, though multi-dose regimens are emerging. Insurance coverage is extremely rare globally; only a few European countries (Spain, Portugal) occasionally reimburse under compassionate frameworks for severe, chronic disability.
Cell therapy for Stroke Recovery is offered as an individualised, physician-led programme. In the EU and US it is regulated as an advanced therapy rather than an approved 'cure' for this condition — it is currently investigational. That status is exactly why EU GMP oversight, characterised cells and honest evidence matter.
Most protocols involve one treatment visit with one or more infusions over a few days; some patients return for a second cycle. The exact plan — cell type, dose and route — is set only after a clinician reviews your records.
Eligibility depends on condition stage, age and overall health. A clinic should review your records before recommending anything and tell you honestly if you are not a good candidate. Our candidacy self-check gives an indicative read in 60 seconds.
An indicative Stroke Recovery programme is €3,000–€8,000 for treatment (it varies by procedure). Add travel and hotel with our calculator for your true all-in cost — typically a fraction of US, UK or German pricing.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
GMP-zertifizierte regenerative Medizin mitten in der EU — ab 3.000–8.000 €, ein Bruchteil der US- oder Deutschland-Preise. Individuelle Protokolle für internationale Patienten aus über 50 Ländern.
Kostenlose ärztliche Prüfung